883
Views
0
CrossRef citations to date
0
Altmetric
Immunotherapy - Cancer

Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy

, , , , , , , , & show all
Article: 2294579 | Received 11 Aug 2023, Accepted 11 Dec 2023, Published online: 18 Dec 2023

References

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–5. doi:10.3322/caac.21660.
  • Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050–6. doi:10.1200/JCO.2017.73.3675.
  • Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). JCO. 2018;36(14):1412–8. doi:10.1200/JCO.2017.77.0388.
  • DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest. 2005;23(2):145–54. doi:10.1081/CNV-50458.
  • Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1978;4(3–4):182–98. doi:10.1016/0360-3016(78)90137-2.
  • Cvitkovic E, Bachouchi M, Boussen H, Busson P, Rousselet G, Mahjoubi R, Flores P, Tursz T, Armand JP, Azli N, et al. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol. 1993;11(12):2434–42. doi:10.1200/JCO.1993.11.12.2434.
  • Wang CJ, Wang CY. Nasopharyngeal carcinoma with leptomeningeal dissemination: case report. Chang Gung Med J. 2000;23:118–22.
  • Redman BG, Tapazoglou E, Al-Sarraf M. Meningeal carcinomatosis in head and neck cancer. Report of six cases and review of the literature. Cancer. 1986;58(12):2656–61. doi:10.1002/1097-0142(19861215)58:12<2656:AID-CNCR2820581218>3.0.CO;2-Q.
  • Geng X, Hao F, Han G, Zhang Y, Qin P. Dural and multiple brain metastases from basaloid nasopharyngeal carcinoma: case report and literature review. Front Oncol. 2021;11:665652. doi:10.3389/fonc.2021.665652.
  • Fakhry C, Bajaj G, Aygun N, Westra W, Gillison M. Long-term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high-dose intravenous methotrexate. Head Neck. 2012;34(2):296–300. doi:10.1002/hed.21516.
  • Naidoo J, Schreck KC, Fu W, Hu C, Carvajal-Gonzalez A, Connolly RM, Santa-Maria CA, Lipson EJ, Holdhoff M, Forde PM, et al. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J Immunother Cancer. 2021;9(8):e002473. doi:10.1136/jitc-2021-002473.
  • Montanarella M, Boldig K, Natter P, Ozdemir S. 18 F-FDG PET/CT Findings of Leptomeningeal Metastasis in Nasopharyngeal Carcinoma. Clin Nucl Med. 2023;48(2):201–2. doi:10.1097/RLU.0000000000004499.
  • Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11(9):871–9. doi:10.1016/S1470-2045(10)70034-6.
  • Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer. 2018;124(1):21–35. doi:10.1002/cncr.30911.
  • Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25(2):103–19. doi:10.1053/ctrv.1999.0119.
  • Twijnstra A, de Visser BW O, van Zanten AP. Diagnosis of leptomeningeal metastasis. Clin Neurol Neurosurg. 1987;89(2):79–85. doi:10.1016/0303-8467(87)90180-6.
  • Ma ATW, Ma BBY, Teo PML, Chan ATC. A novel application of plasma and cerebrospinal fluid level of Epstein Barr virus DNA in the diagnosis of leptomeningeal metastasis from nasopharyngeal carcinoma. A case report. Oncology. 2008;74(1–2):119–22. doi:10.1159/000139140.
  • Larbcharoensub N, Mahaprom K, Jiarpinitnun C, Trachu N, Tubthong N, Pattaranutaporn P, Sirachainan E, Ngamphaiboon N. Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr Virus-associated nasopharyngeal carcinoma. Am J Clin Oncol. 2018;41(12):1204–10. doi:10.1097/COC.0000000000000449.
  • Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162–74. doi:10.1016/S1470-2045(21)00302-8.
  • Zheng M-M, Tu H-Y, Yang J-J, Zhang X-C, Zhou Q, Xu C-R, Jiang B-Y, Yang X-N, Yang X-R, Deng J-Y, et al. Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. Eur J Cancer. 2021;150:23–30. doi:10.1016/j.ejca.2021.03.037.
  • Zhang X, Shu X, Long B. Leptomeningeal metastasis from de novo metastatic nasopharyngeal carcinoma: a case report. Transl Cancer Res. 2022;11(9):3349–56. doi:10.21037/tcr-22-1211.
  • Primdahl D, Cohen-Nowak A, Kumthekar P. Novel approaches to treatment of leptomeningeal metastases. Curr Opin Neurol. 2023;36(6):592–602. doi:10.1097/WCO.0000000000001218.